DDInter1726 DDInter1628
A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Sulfinpyrazone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Sulfinpyrazone {u} (Compound) resembles {v} (Compound) Clotrimazole
Clotrimazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Sulfinpyrazone {u} (Compound) resembles {v} (Compound) Clotrimazole
Clotrimazole {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Sulfinpyrazone {u} (Compound) resembles {v} (Compound) Cinnarizine
Cinnarizine {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Sulfinpyrazone {u} (Compound) resembles {v} (Compound) Phenylbutazone
Phenylbutazone {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Sulfinpyrazone {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) interacts with {v} (Gene) MAST1
MAST1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Sulfinpyrazone {u} (Compound) binds {v} (Gene) ABCC4
ABCC4 {u} (Gene) covaries with {v} (Gene) TSPAN4
TSPAN4 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Sulfinpyrazone {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is associated with {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Sulfinpyrazone {u} (Compound) binds {v} (Gene) ABCC2
ABCC2 {u} (Gene) interacts with {v} (Gene) NFKB1
NFKB1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Sulfinpyrazone {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) regulates {v} (Gene) NUP88
NUP88 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Sulfinpyrazone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Sulfinpyrazone (Compound) resembles Clotrimazole (Compound) and Clotrimazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Sulfinpyrazone (Compound) resembles Clotrimazole (Compound) and Clotrimazole (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Ruxolitinib (Compound)
Sulfinpyrazone (Compound) resembles Cinnarizine (Compound) and Cinnarizine (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Sulfinpyrazone (Compound) resembles Phenylbutazone (Compound) and Phenylbutazone (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Sulfinpyrazone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) interacts with MAST1 (Gene) and MAST1 (Gene) is bound by Ruxolitinib (Compound)
Sulfinpyrazone (Compound) binds ABCC4 (Gene) and ABCC4 (Gene) covaries with TSPAN4 (Gene) and TSPAN4 (Gene) is downregulated by Ruxolitinib (Compound)
Sulfinpyrazone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is associated with hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Sulfinpyrazone (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) interacts with NFKB1 (Gene) and NFKB1 (Gene) is upregulated by Ruxolitinib (Compound)
Sulfinpyrazone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) regulates NUP88 (Gene) and NUP88 (Gene) is downregulated by Ruxolitinib (Compound)